Artículos por temáticas

Amyloid-beta (Aβ₁₋₄₂)-induced paralysis in Caenorhabditis elegans is inhibited by the polyphenol quercetin through activation of protein degradation pathways

Regitz C, Dußling LM, Wenzel U.

Mol Nutr Food Res. 2014 Oct;58(10):1931-40. doi: 10.1002/mnfr.201400014. Epub 2014 Jul 28.

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

McClean PL, Hölscher C.

Neuropharmacology. 2014 Nov;86:241-58. doi: 10.1016/j.neuropharm.2014.07.015. Epub 2014 Aug 8.

Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease

Arai H, Ichimiya Y, Shibata N, Nakajima T, Sudoh S, Tokuda T, Sujaku T, Yokokawa S, Hoshii N, Noguchi H, Bille A.

Psychogeriatrics. 2014 Sep;14(3):165-74. doi: 10.1111/psyg.12055. Epub 2014 Sep 3.

Compassion fatigue in adult daughter caregivers of a parent with dementia

Day JR, Anderson RA, Davis LL.

Issues Ment Health Nurs. 2014 Oct;35(10):796-804. doi: 10.3109/01612840.2014.917133.

A small molecule that displays marked reactivity toward copper- versus zinc-amyloid-β implicated in Alzheimer's disease

Savelieff MG, Liu Y, Senthamarai RR, Korshavn KJ, Lee HJ, Ramamoorthy A, Lim MH.

Chem Commun (Camb). 2014 May 25;50(40):5301-3. doi: 10.1039/c3cc48473d. Epub 2013 Dec 10.

Effect of donepezil in Alzheimer disease can be measured by a computerized human analog of the Morris water maze

Hort J, Andel R, Mokrisova I, Gazova I, Amlerova J, Valis M, Coulson EJ, Harrison J, Windisch M, Laczó J.

Neurodegener Dis. 2014;13(2-3):192-6. doi: 10.1159/000355517. Epub 2013 Oct 30.

[Antipsychotic use in the cohort PACA-Alz in patients with Alzheimer's disease and other dementia in 2010]

Bonin-Guillaume S, Martin G, Zafack J, Gentile G, Allaria-Lapierre V, Sciortino V, Thirion X, Micallef J.

Therapie. 2014 May-Jun;69(3):213-22. doi: 10.2515/therapie/2014015. Epub 2014 Jun 6.

The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease

Ohnishi T, Sakiyama Y, Okuri Y, Kimura Y, Sugiyama N, Saito T, Takahashi M, Kobayashi T.

Curr Alzheimer Res. 2014 Feb;11(2):110-8. doi: 10.2174/15672050113106660167.

Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease

Beauchet O, Launay CP, Allali G, Herrmann FR, Annweiler C.

Drugs Aging. 2014 May;31(5):363-72. doi: 10.1007/s40266-014-0175-3.

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings

Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC.

Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14.

Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease

Poirier J, Miron J, Picard C, Gormley P, Théroux L, Breitner J, Dea D.

Neurobiol Aging. 2014 Sep;35 Suppl 2(Suppl 2):S3-10. doi: 10.1016/j.neurobiolaging.2014.03.037. Epub 2014 May 15.

Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease

O'Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, Kehoe PG, Guyatt G, Molloy DW.

J Alzheimers Dis. 2014;40(3):595-603. doi: 10.3233/JAD-131694.

[Effects of a neuropsychology program based on mindfulness on Alzheimer's disease: randomized double-blind clinical study]

Quintana Hernández DJ, Miró Barrachina MT, Ibáñez Fernández I, del Pino AS, García Rodríguez Jr, Hernández JR.

Rev Esp Geriatr Gerontol. 2014 Jul-Aug;49(4):165-72. doi: 10.1016/j.regg.2014.03.002. Epub 2014 May 28.

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial

Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A, Zisapel N.

Clin Interv Aging. 2014 Jun 18;9:947-61. doi: 10.2147/CIA.S65625. eCollection 2014.

Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product

Sadhu A, Upadhyay P, Agrawal A, Ilango K, Karmakar D, Singh GP, Dubey GP.

Clin Drug Investig. 2014 Dec;34(12):857-69. doi: 10.1007/s40261-014-0235-9.